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The tumor suppressor gene TPS3 encodes for a nuclear 
phosphoprotein involved in the control of cell prolif­
eration, particularly in stressed cells. TPS3 gene muta­
tions are the most frequent genetic event found in 
human cancers. Most mutations locate in the highly 
conserved domains of the gene. Their localizations 
vary according to the tissue and tumor type, but define 
some hot spot regions that may have a certain degree of 
tissue specificity. In certain cases, the type of nucleo­
tide substitutions observed can help to find the carci­
nogenic agent. In recent years, TPS3 gene mutations 
have been frequently observed in human skin tumors. 
In epithelial carcinomas, they involve mainly exons 5, 
7, and 8. Interestingly, many are C to T transitions at 
dipyrimidine sites; particularly, one can find CC to TT 
double-base changes that are known to be specific to 
ultraviolet radiation. These data confirm at the molec-
THE TP53 GENE AND PROTEIN 
The tumor suppressor gene TP53 is the most frequent target gene 
for mutations in human cancer [1,2]. It localizes on the short arm of 
chromosome 17 and is composed of 11 exons interrupted by 10 
introns. The TP53 gene encodes for a 53-kD phosphoprotein, in 
which function is still not clearly defined, but can act as a negative 
regulator of cell proliferation. Its expression is classically located 
within the nucleus but varies during the cell cycle [2,3]. Sequence 
comparison in p53 protein structure between species has revealed 
five clusters of conserved amino-acids designated I to V [4]. Do­
mains I,III, IV, and V are encoded by exons 2,5,7, and 8, respec­
tively, whereas domain II is encoded by both exons 4 and 5. Inter­
estingly, most mutations observed so far interest these highly 
conserved domains [1]. Some of these mutations lead to the produc­
tion of an inactive protein with a significantly prolonged half life 
and/or with new immunogenic properties allowing its detection by 
immunocytochemical methods, whereas the wild type (WT) p53 
protein is undetectable in resting cells [5,6]. 
Another major biochemical property of the WT p53 protein is its 
ability to form polymers with itself and to interact with several viral 
(large T protein of SV 40, E1A protein of adenovirus, E6 protein of 
HPV viruses) and cellular (Hsp 70, murine double minute, or 
MDM2) proteins. These interactions with viral and cellular pro­
teins are known to affect p53 activity and/or degradation [7,8J. 
The function of the p53 protein is still not clear but it has been 
shown to be able to bind to DNA. Moreover, some DNA p53-spe-
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ular level the role of ultraviolet radiation as an impor­
tant etiologic factor in the genesis of these lesions. The 
high incidence of TPS3 mutations suggest that they 
play a role in keratinocyte transformation. Neverthe­
less, this event has not yet been defined as an early or 
late event. 
In melanomas, most studies have shown the detec­
tion of the pS3 protein by immunohistochemistry, 
suggestive of the presence of a mutation in the gene 
prolonging the protein half-life. Anti-pS3 reactivity is 
frequent in these tumors and seems to correlate with 
tumor aggressiveness. Confirmation and characteriza­
tion of TPS3 gene mutation at the DNA level would 
help to precisely define the role of this gene in the 
development of these tumors. Key words: tumor suppres­
sor gene/TPSJ/skin/carcinogenesis.] Invest Dermatol10J: 
102S-106S,1994 
cific sequences have been identified [9,10]. WTp53 has been further 
demonstrated to be able to act as a transcriptional regulator of a 
number of different genes [11 - 17] . Recently, it has been shown 
that the function of p53 is modulated by the product of the onco­
gene murine double minute, MDM2 [18]. The relative ratio be­
tween p53 and MDM2 proteins plays an important role in the 
regulation of cell division. Hence, amplification of the MDM2 
genes has been reported in human cancers [19]. 
Some evidence suggests that WTp53 is important in the control 
of cell growth in stressed cells [20], to permit DNA damage repair. 
This function could be lost in the mutant forms of the protein. 
Recently, p53 expression has been shown to be induced by ultravio­
let (UV) light in human skin [21]. This could protect keratinocytes 
from UV DNA damage favoring skin carcinogenesis. On the 
other hand, mutations of WTp53 within keratinocytes have 
been demonstrated to be induced by UV light leading to the loss of 
the WTp53-protective effect and keratinocyte transformation 
[22-24]. 
The most common genetic alterations described so far in human 
neoplasia are p53 point mutations [1]. These mutations can be ger­
minal in cancer-prone families like the Li-Fraumeni syndrome 
[25,26] or acquired as seen in most sporadic tumors. One or two 
alleles can be affected. If the heterozygosity is not lost, p53 muta­
tions are thought to act as dominant negative mutations (i.e., forma­
tion of an inactive complex between WT and mutated p53) [27] or 
by a dose effect (reduction in WT could affect the phenotype of the 
cl1Jl) [28] . Although TP53 gene mutations are highly variable be-
, tWeen tumor types, they define some hot spots that can have a 
certain degree of tissue specificity. Moreover, in certain cases, the 
localization and type of nucleotide substitution have helped to de­
fine the carcinogenic factor. For example, in hepatocellular carci­
noma, a G to T transversion of codon 249 occurs in geographic areas 
with a high rate of exposure to aflatoxin B 1 [29]. Additionally, the 
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Table I. Immunohistochemical Detection of pS3 Protein in Non-melanoma Skin Cancers 
Reference Antibody Fix. Method SCC 
Stephenson e/ al: PAb 1801 Formalin/ 32/59 
Br] Derma/ol paraffin 54% 
127:566-
570, 1992 
McGregor e/ al: CM1 Formalin/ 11/22 
Br] Derma/ol paraffin 50% 
127:463-
469, 1992 
Roe/al: Br] D07 Formalin/ 15/27 
Derma/ol paraffin 55% 
128:237-
241, 1993 
Urano et at: ] PAb241 Cryosection 5/20 
Dermatol Sci 25% 
4:69-75, 
1992 
PAb 1801 3/19 
16% 
Gutterson et al: JG8/CM1/ Cryosection 3/20 
Oncogene PAb 1801 15% 
6:1785-
1789,1991 
Moles et al: On- CMl Cryosection 0/10 
co gene 8:583- 0% 
588, 1993 
D07 0/10 
0% 
MAb 1801 1/10 
10% 
Ziegler et al: CMl Formalin/ ND 
Proc Natl paraffin 
AcadSci USA 
90:4216-
4220, 1993 
• ND, not done. 
G to T transversion in lung cancer is reminiscent of the same muta­
tion induced in animals by exposure to benzo(a)pyrene, one of the 
main components of tobacco smoke [30]. Mutations of WT p53 
have been demonstrated in some instances as early events in cancer 
formation, but can also participate in tumor progression. Finally, 
inactivation of WT p53 in human cancer can be linked not to a 
mutation but to the formation of inactive complexes with other 
proteins, particularly to the E6 protein of papilloma viruses as ob­
served in cervical carcinomas [31]. Additionally, in some cancer­
prone families, no mutation within the encoding sequence ofTP53 
gene has been found, but the p53 protein is overexpressed [32]. This 
suggests that other, as yet unknown, mutational sites, possibly lo­
cated in the regulatory region of the gene, could exist. 
METHODOLOGY FOR P53 MUTATION ANALYSIS 
Various approaches are used in the literature for the study of P53 
mutations, such as DNA/RNA analysis and sequencin� following 
gene amplification by polymerase chain reaction (PCR). Because a 
number of TP53 gene mutations lead to the prolonged half-life of 
the p53 protein, some studies have used immunohistochemical de­
tection of the protein. 
Only DNA1RNA studies allow a direct confirmation and char­
acterization of the mutation. When using PCR products, however, 
caution must be taken to interpret properly the results, as polymer­
ases can make some mistakes. Repetition of the detection of a muta­
tional pattern is necessary to discriminate between a true mutation 
or an enzymatic artifact. 
Immunolocalization of the p53 protein is possible because a num­
ber of antibodies are commercially available. However, in our expe­
rience, there is not a good correlation between the existence of a 
mutation and the detection of the protein in human skin cancers. In 
a tumor series we have previously characterized for P53 mutation at 
BCC BwD Solar Keratosis Keratoacanthosis 
ND ND ND 4/25 
16% 
14/24 4/5 5/9 8/12 
58% 80% 55% 64% 
11/26 4/12 3/14 0/8 
42% 33% 21% 0% 
0/11 0/4 ND 0/1 
0% 0% 0% 
0/11 0/4 0/1 
0% 0% 0% 
0/10 2/12 0/12 ND 
0% 17% 0% 
2/14 
14% 
2/14 ND ND ND 
14% 
0/14 
0% 
23/25 ND ND ND 
92% 
the DNA level, only three of 11 were found positive for anti-p53 
reactivity, using three different antibodies (007, eMl, Pab1801; 
see Table I, Moles et aQ. This can be explained by certain nonsense 
mutations leading to the absence of synthesis or to the production of 
a truncated protein. However, some missense mutations did not 
permit localizing the protein. Although a technical problem cannot 
be excluded, this could be explained by a difference in conformation 
or epitope accessibility. This is further substantiated by the lack of 
correlation between the detection of the protein with the different 
antibodies. We suggest that several anti-p53 antibodies should be 
used in an anti-p53 assay to minimize the risk of false negatives. 
Additionally, detection of the protein cannot be attributed to gene 
mutation unless confirmed at the DNA level, especially because, as 
cited earlier, some cancers have been shown to be associated with 
the upregulation of the protein without mutation in TP53 coding 
sequence. 
Finally results obtained in cell lines versus fresh tissues can not be 
compared properly, as it has been shown that TP53 gene mutations 
are frequent naturally occuring events in immortilized cell lines and 
should be interpreted cautiously. Studies on fresh tissues are more 
representative of the in vivo situation and should always be preferred 
when available. But tumor tissue is not homogeneous and this can 
lead to dilution and failure to detect the mutation according to the 
limit of sensitivity of the techniques used. Microdissection of the 
tumor tissue has been proposed to overcome that problem. 
TP53 GENE MUTATIONS IN NON-MELANOMA 
SKIN CANCERS 
Within the past few years, an increasing number of reports have 
been published concerning TP53 mutation and protein expression 
in human skin tumors. From these studies, TP53 gene mutation or 
overexpression appears to be a frequent event in epithelial carcino-
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Figure 1o Spectrum ofTPS3 gene mutations in human cancers. Exons are represented by white boxes and introns by straight lines. Black boxes correspond 
to the five conserved block sequences. Vertical bars show point mutations and the number of the affected codon as well as the type of nucleotide substitutions are 
written, (*) specifies dipyrimidine sites. Triangles correspond to microdeletions. Origins of the different studies are given by their corresponding number on the 
scheme: Brash et al (1); Piercall et al (2); Moles et al (3); Campbell et al (4); Rady et al (5); Ziegler et ai, (6); Dumaz et ai, (7). A, TP53 gene mutations in SCC and 
BCC in the general population. B, TP53 gene mutations in BCC and SCC in Xeroderma pigmentosum (XP) patients. 
mas. However, the incidence ofTP53 gene mutation varies among 
series and cancers types. 
In squamous cell carcinomas (SCC), Brash et al found 58% [22] of 
TP53 gene mutations whereas Pierceall et al [24] found 20% and 
Moles et al in our laboratory reported 15% [23]. These differences 
probably result from differences in sampling size (24, 10, and 23, 
respectively) and heterogeneity, and underline the need for larger 
studies to appreciate the role of TP53 gene mutations in these 
cancers. Most mutations reported were located on the highly con­
served domains of the gene. They appeared quite variable among 
and within series but define some hot spot regions in exons 5, 7, and 
8 (See Fig 1). Additionally, certain codons seem to be more affected 
than others such as codons 245, 247/248, 273,278, and 285/286. 
These mutations are essentially point mutations but 3 microdele­
tions have been found in exons 4 and 5. A common feature in all 
studies reported is the frequency of mutations at dipyrimidine sites, 
especially C to T transition, and in Brash et al [22] CC to IT 
double-base changes that are known to be only induced by UV, a 
well-known risk factor for these tumors. Interestingly, a recent 
study has shown that patients with xeroderma pigmentosum, a rare 
hereditary syndrome characterized by a very high incidence of cuta­
neous tumors on sun-exposed body sites due to a deficiency in exci­
sion repair of UV -induced lesions, have a high percentage (40%) of 
TP53 gene mutations, located essentially at CC sequences and from 
which 61 % were tandem CC to IT mutations [34J. Brash et al have 
also shown that all mutations but two were due to translesion syn­
thesis of unrepaired dipyrimidine lesions left on the non-transcribed 
strand. 
Because SCC can originate from the progression of an in situ 
carcinoma (i.e., Bowen's disease [BWd]) , investigators have 
searched for TP53 gene mutations in these lesions. Controversial 
reports have been published. Campbell and colleagues [35] reported 
25% TP53 gene mutations in BW d (n = 20), whereas Moles et al 
did not find any mutation in their series (n = 6). Again, larger series 
should help to identify the role ofTP53 mutation in situ skin carci­
nomas. 
In basal cell carcinomas (BCC), TP53 gene mutations at the 
DNA level have only been reported so far by Rady et al [36], Moles et 
al [23], and more recently Ziegler et al [37], and were found in 50% 
(n = 14), 48% (n = 19), and 56% (n = 27) of the cases studied, 
respectively. All but one microdeletion were point mutations clus­
tered on exons 5, 7, and 8. Codons 196, 248,273,278,282, and 342 
are often affected (see Fig 1). Nucleotide substitutions at dipyrimi­
dine sites were also the main feature observed, suggesting a role of 
UV light in the genesis of these mutations. This is further strength­
ened by the fact that all mutated tumors were located on sun-ex­
posed body sites. This high incidence of P53 mutation in Bce 
suggests that P53 alteration is not related to tumor aggressiveness. 
In most cancers, inactivation ofWT p53 is a two-step process: 1) 
point mutation on one allele and 2) loss of heterozygosity in the 
other. In contrast, the frequency of allelic loss in BCC is very low 
and replaced by a high percentage of sunlight-relate4 point muta­
tion in the second allele [37]. , Thus, TP53 gene mutation is a frequent genetic defect found in 
epithelial carcinomas. Whether it plays a role in the initiation, 
promotion, or progression of skin carcinomas is still a matter of 
debate. 
Beside studies at the DNA level, a number of studies have looked 
for p53 rrotein expression by immunohistochemical methods in 
epithelia skin tumors. From the published literature, it can be said 
that the p53 protein is often detectable in benign (e.g., keratoa­
canthoma [KA]), premalignant (solar keratosis [SK]), and malignant 
(Bwd, BCC, SCC) tissues. The incidence of p53 protein detection 
varies according to skin-samples series, techniques, and antibodies 
used. Interestingly, studies on formalin- and parrafin-embedded tis­
sues seem to give the highest percentage of anti-p53 positivity, even 
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Table ll. Immunohistochemical Detection of pS3 Protein in Melanomas' 
Reference Antibody Fix. Method 
Stretch et al: Cancer Res PAb 240 Paraffin 
51:5976-5979; 
1991 
Bartek et al: Oncogene CM1/PAb421/2 Methacarn/ 
6:1699-1703,1991 40/1801/BP53- paraffin/ 
12/BP53-24 cryosection , 
McGregor et al: Br J CM! Formalin/ 
DermatoI128:606- paraffin 
611,1993 
Ro et al: Br J Dermatol D07 Formalin,! 
128 :237 ..:.241 , 1993 mekcuric 
chloride/ 
paraffin 
Cristofolini et al: Arch CM/Do7/PAb Formalin/ 
DermatoI129:739- 1801 paraffin 
743, 1993 
• ND, not done. 
when using only one anti-p53 antibody (see Table ll). Most inves­
tigators agree on the specific nuclear localization of the p53 protein. 
Some cytoplasmic staining can be observed but is attributed to non­
specific binding or cross reactivity with other cellular components 
such as intermediate filaments [38J. No staining is observed in nor­
mal skin, whatever the technique used. Positive p53 detection in 
see varies from 8% to 56%, in BeC from 0% to 92%, in BW d 
from 0% to 80%, in KA from 0% to 64%, and in SK from 0% to 
550/0 (see Table I, [39,40-44]). Results appear more homogeneous 
among studies performed on formalin-fixed. parrafin-embedded 
tissues, regardless of the antibody used (SCC, 500/0 -560/0; BCC, 
420/0 - 460/0; BW d, 30% -800/0). It would therefore be interesting to 
compare paraffin and cryopreserved sections on the same tissues and 
using the same antibodies to critically define the advantage of the 
former to the latter. 
Although detection of p53 is suggestive ofTP53 gene mutation, 
alternative pathways of WTP53 inactivation should be kept in 
mind as previously discussed, including mutation in the non coding 
sequence affecting the regulation of p53 protein expression, inter­
actions with other proteins, and/or possible post-transcriptional 
Figure 2. Immunohistochemical localization of the pS3 protein 
asiDg 007 monoclonal anti-pS3 antibody (Novocastra. UK). A 
strong nuclear staining is observed in tumor test. No staining is seen in 
normal epidermis or in the dermis. 
Melanoma Dyspla. Neavus Benign neavus 
45/53 ND' ND 
85% 
35/38 ND ND 
92% 
23/36 3/12 0/27 
64% 25% 0% 
1/28 ND 0/19 
3.6% 0% 
17/47 ND 12/75 
36% 16% 
modification of the p53 protein. Some investigators have suggested 
that only tumors in which strong homogeneous p53 immunoreac­
tivity is seen are likely to contain TP53 gene mutations, whereas 
weak and focal staining for p53 reflect post-translational stabiliza­
tion of WTp53 in stressed cells. A comprehensive comparison of 
molecular versus immunohistochemical methods should be inter­
esting to perform on large series especially when one considers that 
small foci of mutated cells present in a largely negative background 
can only be detected by immunohistochemistry. Additionally, cel­
lular pathways leading to the upregulation of the p53 protein in 
human skin are a very interesting field to explore and possibly at the 
origin of important pathomechanisms . 
TP53 GENE MUTATION IN MELANOMA 
A number of cytogenetic abnormalities have been reported in 
human melanomas [45J. Although cytogenic alterations of the 
17 q 13 chromosomal region have not been reported, a recent study 
by Strech et al suggested that submicros€opic changes in the TP53 
gene may be frequent in melanocytic tumors as the p53 protein was 
detected in 85% of surgical specimens tested, (both primary and 
metastatic melanomas) [46]. This, together with the possibility that 
patients with melanoma seem to be at high risk for the development 
of other types of cancers [47J, suggests that some inherited defect 
involving tumor suppressor genes could be implicated. Addition­
ally, melanoma has been associated with Li-Fraumeni syndrome 
[25J, a rare autosomal dominant syndrome in cancer-prone families. 
The role ofTP53 gene mutations in sporadic melanomas has not yet 
been determined. In the Strech study, 45 of 53 p53 positive tumors 
(85%) were detected and the anti-p53 reactivity seemed to correlate 
with the metastatic potential . Other studies have been recently per­
formed on the immunolocalization of p53 protein in melanomas 
(see Table I). Bartek and colleagues [48] found 35 of 38 (92%) 
positive cases using various antibodies. In their comparative analysis 
between metacarn-fixed paraffin-embedded versus frozen sections. 
they found no difference in sensitivity. This could suggest that 
either melanoma cells are less sensitive than keratinocytes to p53 
antigen detection or that technical differences should not be consid­
ered as an explanation for variation in p53 reactivity among studies 
in general. Mc Gregor and colleagues [49] also found a high per­
centage (63%) of p53-positive cells in melanomas that correlated 
with a poor prognosis . In their series, a primary melanoma that was 
initially positive for p53 gave rise to a metastasis in which no p53 
protein could be detected. This suggested that a second mutational 
event affecting the second allele and leading to a null-mutant p53 
occurred. On the other hand, recent reports by Cristofolini et al [50] 
and by Ro et al [44] have found respectively only 360/0 or less (3.6%) 
ofTP53 gene mutations in melanomas. In contrast to other studies , 
they found a low but not negligible percentage of p53-positive 
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benign nevi that hinders the use of p53 staining for the diagnostic 
evaluation of melanomas. Conversely to what is observed in fresh 
tissue, a low percentage ofTP53 mutations has been found in mela­
noma cell lines [51]. 
Comparative genetic and biochemical analysis are still needed to 
precisely define the role of TP53 mutations in melanomas, but 
evidence suggests that it could participate in tumor progression in 
these tumors. 
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